J. Filmus and M. Capurro, The role of glypican-3 in the regulation of body size and cancer, Cell Cycle, vol.7, pp.2787-2790, 2008.

J. Filmus and S. B. Selleck, Glypicans: proteoglycans with a surprise, J. Clin. Invest, vol.108, pp.497-501, 2001.

B. D. Jakubovic, J. , and S. , Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma, Exp. Mol. Pathol, vol.82, pp.184-189, 2007.

M. Allegretta and J. Filmus, Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma, Anti-Cancer Agents Med. Chem, vol.11, pp.543-548, 2011.

M. Ho, K. , and H. , Glypican-3: a new target for cancer immunotherapy, Eur. J. Cancer, vol.47, pp.333-338, 2011.

A. Fico, F. Maina, and R. Dono, Fine-tuning of cell signaling by glypicans, Cell. Mol. Life Sci, vol.68, pp.923-929, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00202709

B. V. Iglesias, G. Centeno, H. Pascuccelli, F. Ward, M. G. Peters et al., Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development, Histol. Histopathol, vol.23, pp.1333-1340, 2008.

H. C. Hsu, W. Cheng, and P. L. Lai, Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution, Cancer Res, vol.57, pp.5179-5184, 1997.

X. Zhou, H. Wang, G. Yang, Z. Chen, B. Li et al., Cloning and expression of MXR7 gene in human HCC tissue, World J. Gastroenterol, vol.6, pp.57-60, 2000.

Z. W. Zhu, H. Friess, L. Wang, M. Abou-shady, A. Zimmermann et al., Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders, Gut, vol.48, pp.558-564, 2001.

Y. Midorikawa, S. Ishikawa, H. Iwanari, T. Imamura, H. Sakamoto et al., Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling, Int. J. Cancer, vol.103, pp.455-465, 2003.

S. Satoh, Y. Daigo, Y. Furukawa, T. Kato, N. Miwa et al., AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1, Nat. Genet, vol.24, pp.245-250, 2000.

M. Kim, A. M. Saunders, B. Y. Hamaoka, P. A. Beachy, and D. J. Leahy, Structure of the protein core of the glypican Dallylike and localization of a region important for hedgehog signaling, Proc. Natl. Acad. Sci. U. S. A, vol.108, pp.13112-13117, 2011.

M. A. Feitelson, B. Sun, N. L. Satiroglu-tufan, J. Liu, J. Pan et al., Genetic mechanisms of hepatocarcinogenesis, Oncogene, vol.21, pp.2593-2604, 2002.

M. D. Thompson and S. P. Monga, WNT/betacatenin signaling in liver health and disease, Hepatology, vol.45, pp.1298-1305, 2007.

L. Wang, M. Yao, L. Pan, Q. Qian, and D. Yao, , 2015.

, Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma, Hepatobiliary Pancreatic Dis. Int, vol.14, pp.361-366

A. O. Kaseb, M. Hassan, S. Lacin, R. Abdel-wahab, H. M. Amin et al., Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma, Oncotarget, vol.7, pp.69916-69926, 2016.

Y. Haruyama and H. Kataoka, Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma, World J. Gastroenterol, vol.22, pp.275-283, 2016.

J. M. Llovet, A. Villanueva, A. Lachenmayer, and R. S. Finn, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat. Rev. Clin. Oncol, vol.12, pp.408-424, 2015.

G. Svensson, W. Awad, M. Hakansson, K. Mani, and D. T. Logan, Crystal structure of N-glycosylated human glypican-1 core protein: structure of two loops evolutionarily conserved in vertebrate glypican-1, J. Biol. Chem, vol.287, pp.14040-14051, 2012.

B. De-cat, S. Muyldermans, C. Coomans, G. Degeest, B. Vanderschueren et al., Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements, J. Cell Biol, vol.163, pp.625-635, 2003.

M. I. Capurro, W. Shi, S. Sandal, and J. Filmus, Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth, J. Biol. Chem, vol.280, pp.41201-41206, 2005.

M. I. Capurro, Y. Xiang, C. Lobe, and J. Filmus, , 2005.

, Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling, Cancer Res, vol.65, pp.6245-6254

S. I. Zittermann, M. I. Capurro, W. Shi, and J. Filmus, Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo, Int. J. Cancer, vol.126, pp.1291-1301, 2010.

M. Feng, H. Kim, Y. Phung, and M. Ho, Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro, Int. J. Cancer, vol.128, pp.2246-2247, 2011.

M. Maurel, S. Jalvy, Y. Ladeiro, C. Combe, L. Vachet et al., A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma, Hepatology, vol.57, pp.195-204, 2013.

B. Laloo, D. Simon, V. Veillat, D. Lauzel, V. Guyonnet-duperat et al., Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method, Mol. Cell. Proteomics, vol.8, pp.1777-1788, 2009.

C. N. Pace, F. Vajdos, L. Fee, G. Grimsley, and T. Gray, How to measure and predict the molar absorption coefficient of a protein, Protein Sci, vol.4, pp.2411-2423, 1995.

Y. Hippo, K. Watanabe, A. Watanabe, Y. Midorikawa, S. Yamamoto et al., Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma, Cancer Res, vol.64, pp.2418-2423, 2004.

A. De-la-coste, B. Romagnolo, P. Billuart, C. A. Renard, M. A. Buendia et al., Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas, Proc. Natl. Acad. Sci. U. S. A, vol.95, pp.8847-8851, 1998.

Y. Wu, H. Liu, H. Weng, X. Zhang, P. Li et al., Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway, Int. J. Oncol, vol.46, pp.1275-1285, 2015.

X. Qi, D. Wu, H. Cui, N. Ma, J. Su et al., Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells, Mol. Med. Rep, vol.10, pp.3177-3184, 2014.

A. Kumar and A. K. Bachhawat, Pyroglutamic acid: throwing light on a lightly studied metabolite, Curr. Sci, vol.102, pp.288-297, 2012.

Z. W. Lai, A. Petrera, and O. Schilling, Protein aminoterminal modifications and proteomic approaches for N-terminal profiling, Curr. Opin. Chem. Biol, vol.24, pp.71-79, 2015.

M. J. Gramer, Product quality considerations for mammalian cell culture process development and manufacturing, Adv. Biochem. Eng./Biotechnol, vol.139, pp.123-166, 2013.

K. Matsuda, H. Maruyama, F. Guo, J. Kleeff, J. Itakura et al., Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells, Cancer Res, vol.61, pp.5562-5569, 2001.

I. Ferna?dez-vega, O. García, A. Crespo, S. Castanõ?, P. Mene?dez et al., Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer, BMC Cancer, vol.13, p.24, 2013.

M. G. Peters, E. Farías, L. Colombo, J. Filmus, L. Puricelli et al., Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model, Breast Cancer Res. Treat, vol.80, pp.221-232, 2003.

Y. Y. Xiang, V. Ladeda, and J. Filmus, Glypican-3 expression is silenced in human breast cancer, Oncogene, vol.20, pp.7408-7412, 2001.

M. Capurro, W. Shi, T. Izumikawa, H. Kitagawa, and J. Filmus, Processing by convertases is required for glypican-3-induced inhibition of Hedgehog signaling, J. Biol. Chem, vol.290, pp.7576-7585, 2015.